| CAS NO: | 54350-48-0 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 354.48 |
|---|---|
| Formula | C23H30O3 |
| CAS No. | 54350-48-0 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 70 mg/mL (197.5 mM) |
| Water: <1 mg/mL | |
| Ethanol: 70 mg/mL (197.5 mM) | |
| Technical info | Chemical Name: ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate InChi Key: HQMNCQVAMBCHCO-DJRRULDNSA-N InChi Code: InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+ SMILES Code: O=C(OCC)/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C=C(OC)C(C)=C1C |
| Synonyms | Tegison, Ethyl etrinoate, Retinoid, Etretinato; Ethyl etrinoate; HSDB 7185; HSDB7185; HSDB-7185; NSC 297936; NSC297936; NSC-297936; Ro 10-9359; Ro 10 9359; Ro109359 |
| In Vitro | In vitro activity: Etretinate(Ro 10-9359) is a second-generation retinoid to treat severe psoriasis; has been replaced by acitretin, a safer metabolite of etretinate. Cell Assay: The HSC-5 cells are plated in 96-well plates at a density of 1.5×103 per 100 μL and used for experiments. Preliminary experiments are performed to determine the effective dose and cytotoxicity of etretinate. The cells are incubated for 72 h with etretinate at concentrations of 5, 10, 25 and 50 nmol/L [dissolved in saline containing 0.0001% dimethyl sulfoxide (DMSO)]. The cells are then incubated for a further 2 h with or without 200 μmol/L ALA (Sigma). Each plate is then irradiated using a metal halide lamp at doses of 10, 20, 40 and 80 J/cm2. |
|---|---|
| In Vivo | There is a significant decrease in mean dermal thickness (P < 0.05) and changes in collagen bundles in the etretinate-treated mice group for a 28-day period compared to control groups. TUNEL assay shows that the density of TUNEL-positive cells in the dermis of etretinate-treated mice for a 14-day period is significantly increased (P < 0.05). The ratio of procollagen α 1 (I) chain to β actin mRNA from etretinate-treated mice for a 1-day period decreased significantly compared to that of the control mice, but the ratio from etretinatetreated mice for a 14-day period increased significantly (P < 0.05). Etretinate reduces dermal thickness, and suppresses the appearance of skin lesions by inducting apoptosis and perhaps regulation of cytokine expression in MRL/lpr mice. |
| Animal model | BLM-induced sclerotic skin mice |
| Formulation & Dosage | Dissolved in peanut oil; 10 mg/kg; p.o. |
| References | Clin Exp Dermatol. 2009 Apr;34(3):385-9; Lupus. 2005;14(7):510-6. |
m.cnreagent.com